Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma

Table 6

Multivariate analysis (mOS).

Parameters	Hazard ratio	95% confidence interval	value
Infusion of CD8^+TIL numbers ( vs. )	5.30	(2.80, 10.03)	<0.0001
Infusion of CD8^+TIL percentage (≥60% vs. <60%)	5.88	(2.85, 12.14)	<0.0001
Infusion of CD8^+PD1^+TIL percentage (≥10% vs. <10%)	6.38	(2.70, 15.08)	<0.0001
Infusion of CD4^+FoxP3^+TIL percentage (≥20% vs. <20%)	4.87	(2.56, 9.84)	<0.0001